Novartis AG's siponimod (BAF312), a second-generation sphingosine 1-phosphate (S1P) receptor modulator designed to be more selective than Gilenya (fingolimod), reduced the risk of disability progression vs. placebo for people with secondary progressive multiple sclerosis (SPMS) during a large phase III study, the company reported. Regulatory filings seeking approval for the therapy are planned for 2019.